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Clinical Outcome of Chemoradiation Therapy in Patients
with Limited-Disease Small Cell Lung Cancer with
Ipsilateral Pleural Effusion
Seiji Niho, MD,* Kaoru Kubota, MD,* Kiyotaka Yoh, MD,* Koichi Goto, MD,*
Hironobu Ohmatsu, MD,* Keiji Nihei, MD,† Nagahiro Saijo, MD,* and Yutaka Nishiwaki, MD*
Background: The indications for definitive thoracic radiotherapy
(TRT) in limited-disease small cell lung cancer (LD-SCLC) and
ipsilateral pleural effusion have not been thoroughly investigated.
We retrospectively investigated the clinical outcome of LD-SCLC
patients with ipsilateral pleural effusion.
Methods: The medical records of SCLC patients who received
treatment at the National Cancer Center Hospital East between July
1992 and December 2006 were reviewed. Sixty-three of the 373
LD-SCLC patients (17%) had ipsilateral pleural effusion. Of these,
62 patients received chemotherapy as an initial treatment, and were
included in this study. Since about 1998, definitive TRT was
routinely performed if the patient’s pleural effusion disappeared
after induction chemotherapy. The 62 patients were divided into
three subgroups: group A included patients who received chemo-
therapy and TRT (n  26), group B included patients who did not
receive TRT in spite of the disappearance of pleural effusion after
first-line chemotherapy (n  8), and group C included patients who
did not receive TRT and whose pleural effusion persisted after
first-line chemotherapy (n  28).
Results: The response rate for first-line chemotherapy was 74%.
Ipsilateral pleural effusion disappeared after first-line chemotherapy
in 34 patients (55%). The median overall survival time was 11.8
months, and the 2 and 3-year survival rates were 21 and 10%,
respectively. In groups A, B, and C, the median survival times were
19.2, 10.5, and 9.2 months, respectively, and the 2-year survival
rates were 38, 25, and 7%, respectively.
Conclusion: Long-term survival was achieved by LD-SCLC pa-
tients with ipsilateral pleural effusion who successfully underwent
chemoradiotherapy.
Key Words: Small cell lung cancer, Limited-disease, Pleural effu-
sion, Chemoradiation.
(J Thorac Oncol. 2008;3: 723–727)
Lung cancer is the leading cause of cancer-related deathsworldwide. In Japan, over 56,000 people died of lung cancer
in 2003. Small cell lung cancer (SCLC) accounts for about 15%
of all forms of lung cancer. SCLC has a more aggressive
biologic behavior than non-small cell lung cancer. At the time of
presentation, two-thirds of patients exhibit disseminated disease.
SCLC is sensitive to chemotherapy, with a response rate of 70 to
80%. A clinical two-stage system proposed by the Veterans
Administration Lung Study Group distinguishes limited-disease
(LD) and extensive-disease (ED) in SCLC.1 LD is defined as
being limited to one hemithorax, including mediastinal, con-
tralateral hilar, and ipsilateral supraclavicular lymph nodes,
whereas ED represents tumor spread beyond these regions. The
current standard care for LD-SCLC is a combination of chemo-
therapy and thoracic radiotherapy (TRT). On the other hand,
ED-SCLC is treated with chemotherapy alone. The original
definition of LDwas a tumor volume that could be encompassed
by a reasonable radiotherapy plan. According to the Interna-
tional Association for the Study of Lung Cancer (IASLC)’s
consensus report, on the other hand, the classification of LD-
SCLC includes bilateral hilar and/or supraclavicular nodal in-
volvement and ipsilateral pleural effusion.2 However, the indi-
cation for definitive TRT in patients with LD-SCLC and
ipsilateral pleural effusion have not been thoroughly investi-
gated. Recently, the IASLC proposed the seventh edition of the
tumor, node, metastasis (TNM) classification for lung cancer. In
the proposals, the presence of a pleural effusion is considered as
M1 disease.3–6
Definitive TRT is contraindicated in lung cancer patients
with malignant pleural effusion. We have sometimes treated
SCLC cases in which the ipsilateral pleural effusion disappeared
after induction chemotherapy. Should definitive TRT be indi-
cated in SCLC patients if the ipsilateral pleural effusion disap-
pears after induction chemotherapy? Since about 1998, we have
routinely performed definitive TRT if the patient’s pleural effu-
sion disappeared after induction chemotherapy. In this retrospec-
tive study, we investigated the clinical course and outcome of
LD-SCLC patients with ipsilateral pleural effusion and exam-
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ined the overall survival in patients who received chemotherapy
and TRT, comparing with that of ED-SCLC or LD-SCLC
patients without ipsilateral pleural effusion. We also applied the
proposed seventh edition of the TNM stage to our cohort.
PATIENTS AND METHODS
We retrospectively reviewed the medical records of
lung cancer patients who received treatment at the National
Cancer Center Hospital East between July 1992 and Decem-
ber 2006. During this period 699 patients were newly diag-
nosed as having SCLC. Three-hundred and seventy-three
patients were diagnosed as having LD-SCLC, and 326 were
diagnosed as having ED-SCLC using conventional staging
procedures, including a medical history and physical exami-
nation, chest radiography, computed tomography (CT) scan
of the chest, CT scan or ultrasound of the abdomen, bone
scan, and CT scan or magnetic resonance imaging of the
brain. In this study, LD-SCLC was defined as disease limited
to one hemithorax, including mediastinal, contralateral hilar,
and supraclavicular lymph nodes, ipsilateral pleural effusion,
and pericardial effusion; ED-SCLC was defined as tumor
spread beyond these manifestations.2 Sixty-three of the 373
LD-SCLC patients (17, 95% confidence interval (CI): 13–
21%) had ipsilateral pleural effusion. Thirty-seven SCLC
patients underwent surgical resection as an initial treatment,
and 13 patients received only TRT and/or best supportive
care. Remaining 649 patients received chemotherapy as an
initial treatment. Of these, 62 LD-SCLC patients had ipsilat-
eral pleural effusion, and were included in this study. The
patient characteristics are shown in Table 1. The breadth of
the pleural effusion was measured using a CT scan of the
chest (Figure 1). Cytologic examination of the pleural effu-
sion prior to treatment was performed in 26 patients. Eleven
patients had cytologically positive effusion. Ten patients also
had pericardial effusion. Three patients had solid pleural
tumor and pleural effusion detected on CT scan. Twenty-six
patients had atelectasis. Of these, 14 patients received cyto-
logic examination of the pleural effusion, and four patients
had cytologically positive effusion.
We collected clinical data on the patients from their
medical records; this data included the chemotherapy regimen
that was received, the response to first-line chemotherapy,
whether pleural effusion disappeared after first-line chemother-
apy, and whether the patient underwent definitive TRT. The
World Health Organization’s response criteria were used.7
Overall survival was defined as the interval between the
start of treatment and death or the final follow-up visit.
Median overall survival was estimated using the Kaplan-
Meier analysis method.8 Survival data was compared among
groups using a log-rank test. The breadth of pleural effusion
was compared using the Mann-Whitney U test. All reported
p values are two-sided.
RESULTS
The induction chemotherapy regimens were shown in
Table 2. Most common regimen was cisplatin or carboplatin
plus etoposide. In LD patients with ipsilateral pleural effu-
sion, there were three complete responses, 43 partial re-
sponses, seven no changes, and six progressive diseases.
Response was not evaluated in three patients because of early
death. The response rate was 74% (95% CI: 62–84%).
Ipsilateral pleural effusion disappeared after first-line chemo-
therapy in 34 patients (55, 95% CI: 42–68%).
FIGURE 1. Ipsilateral pleural effusion. The arrow indicates
the breadth of pleural effusion.
TABLE 1. Patient Characteristics
LD-SCLC without
Ipsilateral Pleural
Effusion
LD-SCLC with
Ipsilateral
Pleural Effusion ED-SCLC
No. of patients 270 62 317
Sex
Male 226 50 262
Female 44 12 55
Age, yr
Median 66 67 66
Range 38–87 46–79 28–85
Performance status
0 71 2 20
1 178 45 203
2 14 10 59
3 6 5 28
4 1 0 7
Breadth of pleural
effusion on CT
scan, cm
Median 2.3
Range 0.5–9.4
Cytology of pleural
effusion
Positive 11
Negative 15
Not examined 36
Patients who received chemotherapy as an initial treatment were included.
LD, limited-disease; SCLC, small cell lung cancer; ED, extensive-disease; CT,
computed tomography.
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Since about 1998, definitive TRT to the primary lesion
and mediastinum was routinely performed in patients whose
pleural effusion disappeared after chemotherapy. We divided
the 62 patients in this study into three subgroups: group A
included patients who received chemotherapy and TRT (n 
26), group B included patients who did not receive TRT in
spite of the disappearance of pleural effusion after first-line
chemotherapy (n  8), and group C included patients who
did not receive TRT and whose pleural effusion persisted
after first-line chemotherapy (n  28).
The median (range) breadth of pleural effusion was 11.2
cm (0.5–7.6 cm) in group A, 1.8 cm (0.5–5 cm) in group B, and
4 cm (0.7–9 cm) in group C. Combining group A and B, the
median breadth of pleural effusion was 1.3 cm, which was
significantly lower than that of group C (p 0.0007) (Figure 2).
In group A, all but two patients received platinum-
based chemotherapy. One patient received weekly cisplatin,
vincristine, doxorubicin, plus etoposide (PE) therapy, and the
other patient received cyclophosphamide, doxorubicin, PE
alternating with cisplatin PE therapy. Three of the 26 patients
in group A underwent TRT (twice daily, 45 Gy in total)
concurrently with the first course of chemotherapy. The
breadths of pleural effusion in those three patients were 0.7,
0.8, and 1.0 cm. Two, seven, and one patient underwent TRT
(once daily, 50 Gy in total) concurrently with the second,
third, and fourth courses of chemotherapy, respectively. Thir-
teen patients underwent TRT (once daily, 50 Gy in total)
sequentially after chemotherapy. Six patients received pro-
phylactic cranial irradiation (PCI) of 25 Gy.
Figure 3A showed the survival of the all 699 SCLC
patients by the proposed seventh edition of TNM stage.
Figure 3B showed the survival of the 649 SCLC patients who
received chemotherapy as an initial treatment. The survival of
LD patients with ipsilateral pleural effusion was intermediate
between those of LD patients without effusion and ED
patients (p  0.0001). The median survival time in LD
patients with ipsilateral pleural effusion was 11.8 months
(95% CI: 9.2–16.6), and the 1, 2, 3 and 5-year survival rates
were 48, 21, 10 and 8%, respectively. Four patients have
survived for over 5 years. One patient had a cytologically
negative pleural effusion, and cytologic examinations were
not performed for the remaining three patients. Breadth of
pleural effusion of these four patients ranged from 1.0 to 1.5
cm. Two of these four patients have not shown any progres-
sion for more than 5 years. One patient who received only
chemotherapy as an initial treatment developed a local recur-
rence 3 years after the first-line treatment. This patient re-
ceived concurrent chemoradiotherapy and achieved a com-
plete response. Unfortunately, he developed brain metastasis
9 years after the first-line chemotherapy and received whole
brain radiotherapy. The other patient developed cervicular
and inguinal node metastases 8 months after the initiation of
first-line chemotherapy and concurrent TRT with three
courses of chemotherapy. This patient received second, third,
and fourth-line chemotherapy, radiotherapy to the cervicular
and inguinal node metastases, and surgical resection of the
recurrent inguinal node metastasis. He has not shown any
signs of progression for 3 years and 3 months after the final
surgical resection of the metastatic inguinal node. All three
patients who had solid pleural tumor died within 31 months.
Survival analyses for the subgroups in LD patients with
ipsilateral pleural effusion are shown in Figures 4, 5 and Table
3. In group A, the median survival time was 19.2 months (95%
CI: 16.7–27.9) and the 1 and 2-year survival rates were 81 and
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FIGURE 2. Breadth of pleural effusion in subgroup A  B,
and C. Group A included patients who underwent chemo-
therapy and thoracic radiotherapy (TRT) (n  26), group B
included patients who did not undergo TRT in spite of the
disappearance of pleural effusion after first-line chemother-
apy (n  8), and group C included patients who did not
undergo TRT and whose pleural effusion persisted after first-
line chemotherapy (n  28). The line represents the median
with the interquartile range.
TABLE 2. Induction Chemotherapy Regimens and
Response
LD-SCLC
without
Ipsilateral
Pleural
Effusion
LD-SCLC
with
Ipsilateral
Pleural
Effusion ED-SCLC
Chemotherapy regimens
Platinum  ETP 252 54 154
Cisplatin and irinotecan
containing regimens
10 2 92*
CODE 7 5 52
CAV/PE 1 1 11
Other 0 0 8
Response
CR 64 3 28
PR 189 43 213
NC 8 7 37
PD 5 6 18
NE 4 3 21
Response rate (%)
(95% CI)
94 (90–96) 74 (62–84) 76 (71–81)
*Nine patients received chemotherapy of cisplatin and topotecan.
LD, limited-disease; SCLC, small cell lung cancer; ED, extensive-disease; ETP,
etoposide; CODE, weekly cisplatin, vincristine, doxorubicin, plus etoposide; CAV/PE,
cyclophosphamide, doxorubicin, plus etoposide alternating with cisplatin plus etopo-
side; CR, complete response; PR, partial response; NC, no change; PD, progressive
disease; NE, not evaluable; CI, confidence interval.
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38%, respectively. The median survival time of patients with
cytologically positive and negative pleural effusion were 9.3
months (95% CI: 3.8–14.2) and 12.7 months (95% CI: 5.1–
17.9), respectively. The median survival time of those patients
whose pleural effusions were not examined cytologically was
12.9 months (95% CI: 9.2–18.4). This difference was not sta-
tistically significant (p  0.1959).
Disease progression was confirmed in 21 of the 26
patients in group A. The sites of first disease progression
included the brain (n  10), regional lymph nodes (n  5),
primary lesion (n 3), distal lymph nodes (n 2), liver (n 1),
adrenal gland (n  1), and bone (n  1). Twelve (57%) were
distant, seven (33%) were local-regional, and two (10%) were
both local-regional and distant. Brain metastasis was the only
site of recurrence in nine patients. These nine patients had not
received PCI. At the time of disease progression, ipsilateral
pleural effusion recurred in 10 of the 18 patients.
DISCUSSION
LD-SCLC with ipsilateral pleural effusion accounted for
9% of all the patients with SCLC (63 of 669 patients) and 17%
of all the patients with LD-SCLC (63 of 373 patients). Twenty-
six (41%) of the LD-SCLC patients with ipsilateral pleural
effusion received chemotherapy and definitive TRT. The me-
dian survival time of these patients was 19.2 months (95% CI:
16.7–27.9), and the 1 and 2-year survival rates were 81 and 38%,
respectively. This overall survival time was comparable to that
of LD patients without ipsilateral pleural effusion.
Among the LD-SCLC patients with ipsilateral pleural
effusion, the median survival time was 11.8 months (95% CI:
9.2–16.6), and the 1 and 2-year survival rates were 48 and
21%, respectively. This survival was intermediate between
those of LD patients without ipsilateral pleural effusion and
ED patients. An analysis of 2,580 patients treated in the
Southwest Oncology Group trials demonstrated that the sur-
vival of patients with LD-SCLC and ipsilateral pleural effu-
sion was not significantly different from that of patients with
ED-SCLC and a single metastatic lesion. The median sur-
vival times were 13.0 and 12.0 months (p  0.85), respec-
tively.9 Thus, our data was compatible with that of the
Southwest Oncology Group trials. Another analysis of 5,758
patients with SCLC from the IASLC database also demon-
strated consistent results.10
According to the proposed seventh edition of the TNM
classification for lung cancer, LD patients with ipsilateral
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FIGURE 3. A, Overall survival in the all 699 patients with
small cell lung cancer by the proposed seventh edition of
the tumor, node, metastasis stage. B, Overall survival in the
649 patients who received chemotherapy as an initial treat-
ment. LD, limited-disease; SCLC, small cell lung cancer; ED,
extensive-disease.
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FIGURE 4. Overall survival in subgroups A, B, and C.
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pleural effusion will be classified as stage IV.3–6 However,
prognosis of LD patients with ipsilateral effusion is better
than that of ED patients with distant metastasis. If surgical
cases such as clinical stage I cases were excluded, the simple
staging system, LD or ED, seemed to be sufficient to select
treatment strategy.
In our study, four LD patients with ipsilateral pleural
effusion have survived for more than 5 years. Three patients
received chemotherapy and TRT as an initial treatment. The
remaining one patient received only chemotherapy as an
initial treatment but received chemotherapy and TRT after a
local recurrence. TRT probably contributed to local control
and long-term survival in those LD-SCLC patients with
ipsilateral pleural effusion. A previous systematic review
demonstrated that an early timing of TRT contributed to a
significant improvement in long-term survival, compared
with a late timing.11 In patients whose ipsilateral pleural
effusion disappears after chemotherapy, definitive TRT
should be considered as early as possible.
Disease progression was confirmed in 21 out 26 pa-
tients (81%) who received chemotherapy and definitive TRT.
The most common site of first failure was the brain. Nine of
the 10 patients had not received PCI. In these nine patients,
brain metastasis was the only site of recurrence. In LD-SCLC
patients with ipsilateral pleural effusion who undergo chemo-
therapy and definitive TRT, PCI may further improve treat-
ment outcome.
Cytologic examinations of the pleural effusion before
treatment were only performed in 26 patients (42%). These
cytologic results did not significantly affect overall survival.
However, all nine patients with cytologically positive pleural
effusion died within 31 months. A similar observation was
reported in a cohort of IASLC database.10
Chemotherapy regimens were heterogeneous between
LD and ED patients. More patients with ED received cispla-
tin and irinotecan containing regimens. However, response
rates were similar between LD with ipsilateral pleural effu-
sion and ED patients (74 and 76%).
In conclusion, long-term survival was achieved by
LD-SCLC patients who underwent definitive TRT after their
ipsilateral pleural effusion disappeared after induction che-
motherapy. A prospective randomized trial is warranted to
compare chemotherapy alone with chemoradiotherapy in LD-
SCLC patients with ipsilateral pleural effusion. This work
was supported in part by a Grant from the Ministry of Health,
Labor, and Welfare for the 3rd term Comprehensive Strategy
for Cancer Control and a Grant-in-Aid for Cancer Research
from the Ministry of Health, Labor, and Welfare, Japan.
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TABLE 3. Survival Data
Subgroup
No. of
Patients
Median Survival Time
(mo) (95%CI)
1-yr Survival
Rate (%)
2-yr Survival
Rate (%)
3-yr Survival
Rate (%)
ED 317 9.8 (8.8–10.6) 37 10 4
LD without ipsilateral pleural effusion 270 20.9 (19.1–22.7) 72 38 29
LD with ipsilateral pleural effusion 62 11.8 (9.2–16.6) 48 21 10
Receiving TRT 26 19.2 (16.7–27.9) 81 38 19
Not receiving TRT 36 9.1 (6.0–10.8) 28 11 6
Not receiving TRT in spite of disappearance of pleural effusion 8 10.5 (4.5–30.6) 38 25 13
Not receiving TRT and persistent pleural effusion after
chemotherapy
28 9.2 (5.1–10.8) 25 7 4
Cytologically positive pleural effusion 11 9.3 (3.8–14.2) 27 9 0
Cytologically negative pleural effusion 15 12.7 (5.1–17.9) 53 20 7
Without cytological examination 36 12.9 (9.2–18.4) 56 28 17
CI, confidence interval; ED, extensive-disease; SCLC, small cell lung cancer; LD, limited-disease; TRT, thoracic radiotherapy.
Journal of Thoracic Oncology • Volume 3, Number 7, July 2008 LD-SCLC with Ipsilateral Pleural Effusion
Copyright © 2008 by the International Association for the Study of Lung Cancer 727
